The interest in the activation of macrophage in DKD was confirmed by a clinical study in patients with DKD and albuminuria who were randomized to NOX-E36, a monocyte-chemotactic protein 1 (MCP-1) inhibitor [43]. Here, CCL2 is linked to diabetic kidney disease.